Selecta Biosciences
480 Arsenal Way
Building One
Watertown
Massachusetts
02472
United States
Tel: 617-923-1400
Fax: 617-924-3454
Website: http://www.selectabio.com/
Email: info@selectabio.com
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
Exchange: NASDAQ
155 articles with Selecta Biosciences
-
Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
5/17/2022
Selecta Biosciences, Inc. announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.
-
Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
Selecta Biosciences, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
5/2/2022
Selecta Biosciences, Inc. announced six upcoming presentations, including three joint presentations with our partner AskBio, at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, to be held virtually and in-person from May 16-19, 2022 in Washington, D.C.
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
4/28/2022
Selecta Biosciences, Inc. (NASDAQ: SELB), today announced that it plans to host a conference call on Thursday, May 5, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.
-
Selecta Biosciences Announces $38.7 Million Underwritten Offering
4/6/2022
Selecta Biosciences, Inc., a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, announced that it has agreed to sell 27,428,572 shares of its common stock and accompanying warrants to purchase up to 20,571,429 shares of common stock at a combined offering price of $1.41 per share and accompanying warrant.
-
Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference
4/4/2022
Selecta Biosciences, Inc. announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the 21st Annual Needham Virtual Healthcare Conference, to be held virtually April 11-14, 2022.
-
Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.
-
Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
3/10/2022
Selecta Biosciences, Inc. reported financial results for the quarter and full year ended December 31, 2021 and provided a business update.
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Provide Business Update
3/3/2022
Selecta Biosciences, Inc. today announced that it plans to host a conference call on Thursday, March 10, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021 and provide a business update.
-
Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
2/9/2022
Selecta Biosciences, Inc. announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.
-
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
1/10/2022
Selecta Biosciences, Inc., a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks, the leading horizontal platform for cell programming, announced a collaboration to develop safer and more effective next-generation gene therapy viral capsids.
-
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
1/5/2022
Selecta Biosciences, Inc. announced that Company’s Management will provide a corporate update at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.
-
Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event
12/29/2021
Selecta Biosciences, Inc. announced that Company’s Management will participate in a panel and one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout
12/1/2021
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development programme of SEL-212 for chronic refractory gout.
-
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
12/1/2021
Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI), today announced the completion of enrollment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development program of SEL-212 for chronic refractory gout.
-
Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions-
11/24/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Phase 1/2 clinical trial of SEL-302 (which consists of MMA-101 plus ImmTOR) for the treatment of patients with methylmalonic acidemia (MMA).
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference
11/11/2021
Selecta Biosciences, Inc. today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held virtually November 18-19, 2021.
-
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
11/9/2021
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update